Search Results
Jennifer Green, EASD 2022: Finerenone & Empagliflozin in patients with CKD and T2D: CONFIDENCE Study
Radcliffe & CardioNerds @AHA22: EMPA-Kidney: Empagliflozin & CV Outcomes in Patients with CKD
Safety evaluation of empagliflozin for patients with type 2 diabetes and chronic kidney disease
George Bakris, MD | Use of Finerenone in Patients with Diabetes Who Have Kidney Disease
26 Mohamed Tarik Bakri New horizons in Management of Patients with CKD in T2D – Role of Finerenon
Effects of canagliflozin versus finerenone on cardiorenal outcomes
EMPA-Kidney Results
"Preventing Cardiovascular Disease & CKD Progression in T2 Diabetes Assoc. CKD", Dr. Rajiv Agrawal
Finerenone: Evaluating and Understanding this Drug as Treatment
Nonsteroidal mineralocorticoid receptor antagonists & cardiorenal outcomes in chronic kidney disease
LIVE #EASD22 ADA/EASD consensus report interview with John Buse
Chantal Mathieu, EASD 2022: Once Weekly Insulins: Insulin Icodec
